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Abstract
Purpose 18F-Labelled fluorodeoxyglucose (FDG) can detect
early changes in tumour metabolism and may be a useful
quantitative imaging biomarker (QIB) for prediction of dis-
ease stabilization, response and duration of progression-
free survival (PFS). Standardization of imaging procedures
is a prerequisite, especially in multicentre clinical trials. In
this study we reviewed the quality of FDG scans and com-
pliance with the imaging guideline (IG) in a phase III clin-
ical trial.
Methods Forty-four cancer patients were enroled in an imag-
ing sub-study of a randomized international multicentre trial.
FDG scan had to be performed at baseline and 10–14 days
after treatment start. The image transmittal forms (ITFs) and
Digital Imaging and Communications in Medicine (DICOM)
[1] standard headers were analysed for compliance with the
IG. Mean liver standardized uptake values (LSUVmean) were
measured as recommended by positron emission tomography
(PET) Response Criteria in Solid Tumors 1.0 (PERCIST) [2].
Results Of 88 scans, 81 were received (44 patients); 36 were
properly anonymized; 77/81 serum glucose values submitted,
all but one within the IG. In 35/44 patients both scans were of
sufficient visual quality. In 22/70 ITFs the reported UT dif-
fered by >1 min from the DICOM headers (max. difference
1 h 4 min). Based on the DICOM, UT compliance for both
scans was 31.4 %. LSUVmean was fairly constant for the 11
patients with UT compliance: 2.30±0.33 at baseline and 2.27
±0.48 at follow-up (FU). Variability substantially increased
for the subjects with unacceptable UT (11 patients): 2.27±
1.04 at baseline and 2.18±0.83 at FU.
Conclusion The high attrition number of patients due to low
compliance with the IG compromised the quantitative
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assessment of the predictive value for early response monitor-
ing. This emphasizes the need for better regulated procedures
in imaging departments, which may be achieved by education
of involved personnel or efforts towards regulations.
LSUVmean could be monitored to assess quality and compli-
ance in an FDG PET/CT study.
Keywords Quantitative imaging biomarker . PET/CT . PET .
Quality control . Quality assurance .Multicenter clinical
study . Standartization . Harmonization . Retrospective
review . Guidelines
Introduction
Quantitative imaging biomarkers (QIBs) for molecular imag-
ing, such as 18F-labelled fluorodeoxyglucose (FDG), have the
potential to predict response to therapy early, before changes in
tumour size occur. Therefore, molecular imaging could be used
for early treatment stratification and modification. Morpholog-
ical measurements of pathology {e.g. using Response Evalua-
tion Criteria in Solid Tumors (RECIST [3])} have disadvan-
tages in the era of targeted therapy with cytostatic molecules,
as tumour size changes do not always occur early. New
methods for evaluating response to treatment such as molecular
imaging could overcome this challenge. When QIBs become
validated endpoints, this has important clinical implications as
ineffective treatment can be modified earlier. Several publica-
tions have shown the utility of FDG positron emission tomog-
raphy (PET)/CT for early detection of changes in pathology and
correlation with patients’ outcome [4, 5]. The advantages of
using biochemical QIBs over morphological in the assessment
of cytostatic molecules continues to gain acceptance [6], includ-
ing patient stratification and prognostic impact before therapy is
initiated [7]. However, this requires standardized and reproduc-
ible image acquisition, reconstruction and evaluation. Standard-
ization and harmonization of PET/CT in multicentre clinical
studies is now well developed after much effort was put into
it within the past few years from professional organizations
such as the Society of Nuclear Medicine (SNM), European
Association of Nuclear Medicine (EANM) and Quantitative
Imaging Biomarkers Alliance (QIBA). Despite that, assessment
of sites’ compliance with the imaging guideline (IG) in
multicentre clinical studies is usually not performed in many
trials and only a handful of publications of actual results could
be found.
The objective of this study is to explore the need to perform
an extensive prospective quality control (QC) on imaging data
collected during the course of a study assuring that imaging
data actually meet the quality standards needed to address the
question at hand. To this end, a retrospective analysis of im-
aging data collected during a clinical trial was performed.
Materials and methods
Between October 2008 and February 2010, 369 patients with
soft tissue sarcoma whose disease has progressed during or
following prior therapy were randomly assigned to receive
pazopanib or placebo in the EORTC 62072/VEG110727
phase III clinical trial. The results of the main study were
published in 2012 [8]. During this trial patients were offered
the opportunity to participate in an FDG PET/CT imaging
sub-study. The objective of this imaging sub-study was to
investigate whether early changes in tumour metabolism as
determined by the maximum standardized uptake value
(SUVmax) were predictive for disease stabilization, response
or duration of progression-free survival (PFS). The hypothesis
underlying this imaging sub-study (for which 50 patients were
planned) was that for a clinically relevant endpoint in patients
with a PET response (=25 % decrease in SUVmax) the PFS
was 12 weeks longer than in patients without PET response.
The prognostic and predictive value of SUVmax on the base-
line (BL) and follow-up (FU) FDG PET/CT was to be evalu-
ated independently. As inter-institutional variations in SUV
were expected due to scanner and protocol differences, the
imaging protocol demanded strict adherence to standardized
acquisition and processing parameters. In this retrospective
analysis, evaluation of compliance with the IG directly affect-
ing the quantification of PET results (e.g. SUV) and interna-
tional standards was performed by assessing presence of im-
age artefacts, reviewing the FDG uptake in the liver and ver-
ification of scanning-related parameters, such as uptake time
(UT), from information available in Digital Imaging and
Communications in Medicine (DICOM) headers and image
transmittal forms (ITFs).
Eligibility and recruitment
In order to be eligible for this imaging sub-study, patients had
to participate in the EORTC 62072/VEG110727 trial. In ad-
dition to the eligibility criteria for the main trial [8], the pa-
tients had to meet the following criteria:
& Separate written informed consent for the imaging sub-
study.
& At least one tumour lesion ≥2 cm located outside the bone
or bladder region.
& Serum glucose ≤200 mg/dl (11 mmol/l). Correction of
elevated glucose levels with short-acting insulin was not
permitted.
& FU scan if the BL scan showed FDG uptake tumour to
background ratio ≥2.
& In case all known metastatic lesions proved to be FDG
negative at BL, these patients were not eligible for FU
FDG PET and should be replaced.
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Imaging guidelines
A kick-off meeting was organized for all sites and all involved
in the study and sub-studies where the IG were discussed to
ensure sites could comply. Both PET and PET/CT systems
were acceptable. Whole-body FDG had to be performed at
two time points: BL (within 2 weeks prior to treatment start)
and early FU (approximately 10–14 days after start of
treatment).
The proposed acquisition and analysis complied with the
National Cancer Institute (NCI) guidelines as given in
Shankar et al. [9]:
& Fasting period of a minimum of 4 h prior to FDG
administration.
& Prior to imaging, patients were encouraged to drink 700–
1,000 ml of water.
& Sedatives such as diazepam were allowed at the discretion
of the clinician. However, if this was performed for the BL
scan, the amount and timing of the sedative had to be
recorded and repeated in the same way for the FU scan.
& Suggested FDG activity 2.5–5.0 MBq/kg, allowed to be
individualized depending on the type of scanner and pa-
tient habitus per local standard of care.
After intravenous (IV) FDG injection, normal saline was to
be used to flush the administration system. The amount of
radioactivity in the syringe had to be measured before and after
the injection to calculate the net injected dose of FDG, be re-
ported on the ITF and entered accordingly in the scanner. The
administration of IV diuretic (e.g. furosemide 10–20 mg) was
allowed and had to be given 10–15 min after tracer administra-
tion. The patient was to void immediately before scan start.
Given the major impact of UT on SUV [9], the UT was
required to be 60 min with maximum acceptable deviation of
±5 min. The UT of the BL scan had to be recorded and the
same UT had to be used for the FU scan.
Both FDG scans were acquired and images were recon-
structed using local procedures, but it was mandated that each
of the scans within the same patient was processed with ex-
actly the same protocol and specifications (same scanner, UT,
scanner setting for acquisition and reconstruction, axial body
coverage area). Both 2D and 3D acquisitions were allowed, as
long as the technique was identical for both scans.
Imaging sites and scanner calibration
Eleven sites agreed to participate in this sub-study, all large
academic institutions. Inter-institutional variations in SUV
due to scanner and protocol differences were expected. There-
fore, strict adherence to standardized acquisition and process-
ing protocols was required together with calibration of the
PET and PET/CT scanners used in this study prior to first
patient enrolment.
In order to verify image quality, consistency of acquisition
and to ensure sites could export the image data to a central data
storage, upload of an anonymized test data set to a central
server was requested prior to recruitment of patients.
It was specified in the IG that all scans had to be submitted
in standard DICOM format for central data storage within 48 h
of acquisition. An ITF had to be submitted along with every
scan. The ITFs and DICOM headers were analysed retrospec-
tively for compliance with the requirements indicated in the
IG. Proper image anonymization was verified as well, i.e.
replacing patient name and hospital ID with the provided se-
quential ID for the study.
Assessment of the scans
& Visual scoring for quality of the scans was planned using a
three-point scale (good: absence of artefacts, good signal
to noise; intermediate: absence of artefacts and reasonable
signal to noise; poor: presence of artefacts and very low
signal to noise) by consensus from three expert readers.
& For the lesions identified for RECIST on the diagnostic
CT scans stipulated in the main protocol, SUV were mea-
sured in the region of interest of each lesion and were
normalized for body weight, but uncorrected for blood
glucose values. SUVmax, being defined as the maximum
single voxel SUV within the region of interest, was used
for the quantification of the lesions and had to be mea-
sured on the same tumour lesions at BL and during
therapy.
& For QC of the FDG distribution, a volume of interest
(VOI, range 12.34–14.7 cm3) was drawn on the PET im-
ages in an area of normal liver tissue containing homoge-
neous FDG distribution. The mean liver standardized up-
take value (LSUVmean) was used as an additional QC pa-
rameter as it becomes more and more accepted in the
nuclear medicine community. It is an indirect and com-
bined measure of scanner calibration, net injected dose,
proper administration and clock synchronization. The
LSUVmean in a 3D VOI can be expected to be well within
the 1–3 range [2].
Results
Patient recruitment and scan collection
Enrolment of 50 patients into the PET sub-study was planned.
However, since the main trial accrued very rapidly while the
IGwere developed at a rather late stage, only 44 patients could
actually be enroled which should have resulted in 88 scans (1
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BL and 1 FU scan per patient). Of 88 scans, 81 were uploaded
to the central database. In two patients there was no definitely
metabolically active lesion at BL so no FU scan was per-
formed; two patients were never included in the PET imaging
protocol as they did not meet the screening criteria for the
imaging sub-study; two patients were taken off the study be-
fore the FU FDG scan was performed and in one patient the
BL scan could not be retrieved by the site.
Of the 81 scans received, proper anonymization had been
performed on 36 scans by the sites submitting the scans. This
includes at least replacement of the patient name and hospital
ID with the respective enrolment subject number in all
DICOM images submitted.
Imaging sites, scanner calibration and test data
General site visits were performed, but not specific to the FDG
imaging. Due to a more rapid patient accrual than foreseen in
the main study, late integration of this FDG sub-study and lack
of resources, scanner calibration before enrolment of patients
proved to be unfeasible, nor was the collection of individual
phantom scans for review of reconstruction parameters and
image quality evaluation under specified conditions. Of 11
sites, 6 submitted test data prior to patient accrual; the other
sites denominated their first patient’s scan as the test data scan.
Retrospective review of DICOM headers in the six test data
scans revealed that in three data sets the UT was outside the
specifications in the IG.
Serum glucose compliance
According to the IG, serum glucose values should have been
submitted for each of the 81 scans and determined prior to
each scan. Of 81 serum glucose values, 77 were submitted,
all but 1 being within the limits set out in the guidelines:
average 97 mg/dl (5.4 mmol/l), median 94 mg/dl (5.2 mmol/
l), range 61–200 mg/dl (3.4–11.1 mmol/l). At FU, one patient
with serum glucose of 200 mg/dl was reported as diabetic, but
not indicated on the ITF for the BL scan.
Visual quality assessment
A retrospective review and visual quality assessment was per-
formed on all 81 scans received by three nuclear medicine
physicians by consensus using OsiriX (www.osirix-viewer.
com) software. In 35/44 patients both scans were received
and of sufficient quality to perform visual assessment. The
quality of the BL scan was good in 88.6 % of patients and
intermediate in 11.4 %. The same results were observed for
the quality of the FU scans. Figure 1 includes representative
artefacts observed during the visual assessment.
FDG UT compliance
The UT is a major factor affecting SUV [9]. It was observed
that the UT in the DICOM headers in some instances was
different from the information provided on the ITF, often out-
side of the prescribed 60±5 min as per the IG. For these
reasons, a complete review of both scans was done in the 35
visually assessable patients. The injection and scan start time
from the DICOM headers (using the OsiriX software) and ITF
were recorded and compared. In 22/70 ITFs, the UT differed
by more than 1 min from the UT in the DICOM headers; the
maximum difference was 1 h 4 min.
We considered the UT retrieved from the DICOM headers
reliable and representative for the actual UT (Fig. 2a) com-
pared to the UTmarked on the ITF (Fig. 2b). Compliance with
the IG with regard to UT for both scans was 31.4 % (11/35
patients). The actual BL UT±10 min at FU resulted in 66 %
compliance (23/35). However, due to the uncontrolled diabe-
tes in 1 patient, 22/35 patients were considered for semi-
quantitative assessment using SUVmax. Furthermore, due to
technical problems with the PET system, FU scans for two
patients were acquired on different scanners.
Consistent scanning between BL and FU
& Same scanner
In 2/35 patients different PET/CT systems were used for
the BL and the FU scans due to scanner breakdown (Table 1).
Information on the reconstruction method to confirm consis-
tency was not available.
& Scan direction
Keeping scan direction consistent between a BL and all FU
scans is paramount. In 2/35 patients the scan direction was
changed between BL and FU and in 2/35 the scan direction
could not be determined based on the DICOM tags’ informa-
tion most likely due to either anonymization or scanner stan-
dard of functionality (Table 1).
& Time per bed
In 3/35 patients there was minor change in time per bed
between BL and FU (≤4 s), and in 1/35 the difference was
50 % increase from BL to FU (Table 1). For the latter case,
dose change from BL to FU was 18.8 % decrease, while no
patient weight change was reported.
All confounding factors together (scan visual quality, devi-
ations in UT, deviations in scanning protocol, scanner change)
resulted in an ultimate sample size too small to perform the
quantitative analysis for prognostic and predictive factors.
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LSUVmean
The LSUVmean was measured via VOI in 34/35 patients (68
scans), whose scans were considered visually acceptable. In 1/
35 subjects normal liver uptake could not be reliably identified
due to extensive hepatic tumour deposits.
Average and range of LSUVmean data were assessed for
scans falling into three ‘qualitative’ categories:
& UTaccording to the IG for both FDG scans 60±5 min (11
patients)
& UT of FU FDG scan within the actual BL UT±10 min,
irrespective of the absolute UT of the BL scan (12
patients)
& UT outside the specifications of the IG and more than
10 min difference between BL and FU scan (11 patients)
As shown in Fig. 3, LSUVmean was fairly constant among
the 11 patients with excellent UTcompliance and very low SD
of the LSUVmean: 2.24±0.33 at BL and 2.27±0.48 at FU.
Variability in SD of LSUVmean substantially increased for
the subjects with UT outside the acceptable range (11 pa-
tients): 2.27±1.04 at BL and 2.18±0.83 at FU.
Discussion
The variability in local standard of care in the use of PET/
CT across centres has been well documented [10, 11]. The
results from this multicentre international FDG sub-study
confirm that this has a large impact on data with FDG
scans used for primary endpoint. Providing IG to the sites
is not sufficient. While retrospective QC is useful to iden-
tify compliant and noncompliant data, the results from
this study clearly demonstrate that prospective QC is of
the utmost importance as it has an impact on study out-
come [12]. In retrospect, it is almost impossible to retrieve
the necessary data or to have any impact on improving
quality. As documented by Velasquez et al. [13], central-
ized QA in the multicentre multiobserver settings greatly
improves the final outcome. The results presented here
confirm that prospective rapid QC review and feedback
is mandatory to improve compliance with the IG, and is
imperative to ensure that imaging data used for endpoints
are in fact reliable, rather than a mere reflection of change
in imaging technique used. Besides general site visits by
monitors, specific site visits with respect to the imaging
scans would improve both compliance and quality.
Fig. 1 Representative artefacts
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Some sources of error in PET quantification can be
readily identified. Unfortunately, it is an inevitable
shortcoming that the injection time in the DICOM header
is stored by manual input in the scanner computer, and
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Fig. 2 a UT between FDG
injection and start of the PET
scan, based on DICOM tags bUT
between FDG injection and start
of the PET scan, based on ITFs
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these data cannot be stored appropriately in the DICOM
header. As it is impossible to separately store information
on the injection time and the calibration time, the operator
has to choose, resulting in one missing time point. Fur-
thermore, sponsors rely on the sites to ensure synchroni-
zation of all clocks in the PET department. It is felt that
instances of erroneous input of injection time and non-
synchronization of clocks reflect the real world situation,
but are rather very infrequent. Studies have shown the use
of LSUVmean as a reliable marker for QC purposes of
scans longitudinally [14]. The data presented here confirm
that compliance with the IG has a significant impact on
this parameter, and it should be considered as a metric
during QC of FDG scans.
Design and execution of a multicentre international imag-
ing sub-study as part of a larger clinical study (i.e. translational
research study) requires extensive planning with many con-
siderations. Proper power calculation of the study should
Table 1 Reconstruction parameters
Site code PET slice thickness (mm) Scan direction Scanner FDG dose (MBq) Time per bed (s) Reconstruction method
A 2 Cranial Siemens Biograph 16 272–378 180 OSEM2D 5i8s
B 4 Cranial Philips Allegro Body© 312–400 180 3D-RAMLA
B 4 Cranial Philips GEMINI TF TOF 16 192–195 120 3D-RAMLA
C 3.27 Cranial GE Discovery ST 221–258 180 3D FORE IR
D 5 Cranial Philips GEMINI TF© 191 90 BLOB-OS-TF
D 5 Cranial Philips GEMINI TF TOF 16 164–238 60–90 BLOB-OS-TF
E 3.38 Cranial Siemens Biograph Duo 202–370 240 OSEM2D 2i8s
F 4 Cranial Philips Allegro Body(C) 349–369 120 3D-RAMLA
F 4 Cranial Philips GEMINI TF© 349–371 120 BLOB-OS-TF
F 4 Cranial Philips GEMINI TF TOF 16 369–407 120 BLOB-OS-TF
G 2.43 Cranial Siemens Biograph Duo 275–343 210 OSEM 2i8s
H 3.27 Cranial GE Discovery STE 379 150 3D IR
I 4.25 Cranial GE Discovery LS 323–381 86–240 OSEM
I 4.25 Caudal GE Advance 331–381 240 Unknown
J 4 Caudal/cranial Philips GEMINI TF© 235–291 120 BLOB-OS-TF
K 2 Cranial Siemens Biograph 16 706–812 240 OSEM2D 4i8s
K 3.27 Cranial GE Discovery ST 645–813 300 OSEM
Fig. 3 Liver SUVmean in normal liver tissue a UTwas according to the
IG for both FDG scans: 60±5 min (11 patients). b UT of FU FDG scan
was within the UT of the actual BL scan±10 min, irrespective of the
absolute UT of the actual BL scan (12 patients). c UT outside the
specifications of the IG and more than 10 min difference between BL
and FU scan (11 patients)
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include certain excess attrition rate due to poor quality of
scans, patient dropout or ineligibility based on BL scan. At
the time of this project, no reliable data in the literature were
available to suggest what could be a reasonable number of
attrition for the above-noted reasons. Proper on-site training
of all involved staff and prospective QC with rapid feedback
to sites could improve compliance and quality of the collected
imaging data and are prerequisite to obtain data sets with
sufficient statistical power for making study-related
conclusions.
Poor compliance with the study IG and inadequate
quality of scans, when major artefacts are observed af-
fecting visual and quantitative assessment, should be
identified and reported to the sites and the sponsor im-
mediately prior to the FU scan or the next patient en-
rolment. Mandatory test data submission and review,
prompt feedback to sites and site authorization pending
test data approval have proven very important, leading
to increased and sustainable compliance with the imag-
ing protocol [12, 15]. The recently proposed approach
by van den Hoff et al. [16], allowing comparison of
data sets from different acquisition times, may correct
for differences in UT. However, it may not be per-
formed with the same accuracy on other data sets or
may need some data set-specific recalibration. In gener-
al, avoiding the need for corrections or at least mini-
mizing the potential impact of any correction should be
preferred. Thus, performing the studies with standard-
ized imaging procedures should be the aim.
To reach an international standardization and harmo-
nization in the use of QIBs in multicentre clinical stud-
ies, producing high-quality reliable results, it is para-
mount to ensure prospective QC in the execution of
the imaging protocol and obligatory compliance with
the specified parameters. It was not until the second
half of 2011 that the US Food and Drug Administration
(FDA) published central review charter draft guidelines
[17] for the industry, addressing both challenges in part.
In clinical studies where efficacy is assessed with the
aid of QIBs, the imaging protocol should become a
regulatory document and complied with in the same
regard as the actual clinical study protocol. The sponsor
has an obligation to ensure that the study protocol man-
dates strict compliance with the IG and a plan for pro-
tocol violations should be put in place.
Molecular imaging with QIBs could have a major
impact benefiting patients (earlier start of alternative
treatment or spare of side effects in case of ineffective
treatment) as well as the health care system (lower fi-
nancial burden associated with ineffective treatment).
For clinical studies, this may lead to a shorter duration
of trials, improved cost-effectiveness and faster approval
of compounds by the regulatory agencies. Pay for
performance or P4P is a programme initiated in the
UK [18] (in 2004) and the USA (in 2005) aiming to
ensure high-quality health care delivered to patients is
rewarded. In 2008 the Medicare Improvements for Patients
and Providers Act [19] (MIPPA) was accepted. It applies to
physicians, non-physician practitioners and independent diag-
nostic testing facilities as suppliers of imaging procedures
who are submitting claims for the technical component of
advanced diagnostic imaging procedures. All such suppliers
in order to receive reimbursement from the Centers for Medi-
care andMedicaid Services (CMS) are obligated to obtain and
maintain accreditation of their imaging facilities. However,
PET/CT scanners used for imaging patients in multicentre
clinical studies require further harmonization. At the time this
FDG sub-study design was finalized (2008), no formal pro-
gramme for cross-calibration of scanners existed. Since then,
the SNM Clinical Trials Network (CTN) [20], American Col-
lege of Radiology (ACR) [21] and EANM Research Ltd
(EARL) [22] have developed programmes for PET/CT scan-
ners’ harmonization and qualification to participate in
multicentre clinical studies. However, a requirement by formal
government or regulatory agencies to mandate the use of those
programmes has not yet been proposed. It is in the best interest
of the public, the academia and the pharmaceutical industry to use
the accreditation programmes effectively and rigorously, ensuring
data comparability across sites and longitudinal patient’s scans.
Standardized imaging protocols for FDG scans have been
published by Shankar et al. [9] and Boellaard et al. [23] and
are available for implementation within multicentre clinical
studies. A more recent publication in the process of finaliza-
tion is the effort of the QIBA Profile: FDG PET/CT as an
Imaging Biomarker Measuring Response to Cancer Therapy
with the Uniform Protocols in Clinical Trials (UPICT) [24].
Yet from a recent publication by Rausch et al. [25] it is clear
that day-to-day practice is far from standardized in a single
country.
Imaging sub-studies should be developed in parallel with
the main study to ensure readability of the translational re-
search project at the same time as the main study. A recent
publication from Josephson et al. [26] discussed many of the
barriers in front of drug development as to the use of QIBs in
translational sub-studies. In addition, a very basic factor such
as rapid recruitment in the main study, later start of the imag-
ing sub-study and inability to recruit enough patients for the
latter must be seriously considered. The sponsor must foresee
possible inability to achieve the preplanned statistical design,
leading to an underpowered sub-study, or even the main study
(if QIBs are used for the endpoints and compliance is poor),
which could also be due to low compliance and quality of the
scans.
Great effort has been undertaken by the SNM and EANM
towards the importance of understanding International Con-
ference on Harmonization-Good Clinical Practice (ICH-GCP)
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guidelines and ensuring that the imaging department staff is
trained in GCP. Yet little to no support has been given to this
goal from the pharmaceutical industry or recruiting investiga-
tors at sites. Increased GCP education for the imaging person-
nel involved in the chain of patients’ scans from the ordering
of scans to the delivery of the imaging data to the sponsor will
improve the results. If a patient is referred for a PET scan, yet
the imaging department is not informed that the patient is
taking part in a specific clinical study, requiring the use of
an imaging protocol different from the local routine clinical
practice, this could hamper compliance and result in a high
attrition rate of data for the endpoint of the sub-study. The
results from this review indicate that low compliance with
the IG warrants intense education on the basic GCP principles
such following the prescribed IG and properly de-identifying
the data submitted to the sponsor.
Validation of FDG scans for early treatment response and
patient stratification has great potential, but is pending due to
conflicting results being presented in the literature, while no
data on IG compliance are required to be published by the
investigators and the sponsors as of yet.
Conclusion
The use of QIBs in patient care and novel therapies is feasible,
but only when all involved in the clinical study jointly aim at
achieving high quality. A QIB such as FDG is a very sensitive
marker to IG deviations, requiring strict adherence to protocol.
Rigorous compliance with the IG is as crucial as compliance
with the clinical protocol, as shown in this study. IG noncom-
pliance with respect to UT resulted in a large variability in
LSUVmean and could possibly affect tumour uptake quantifi-
cation. Effective approaches in the use of QIBs have been
proposed by various academic groups and scientific societies.
Regulatory authorities, the pharmaceutical industry (including
imaging companies) and investigators play a pivotal role in
developing and implementing standardized processes for the
use of QIBs. Increased education of the imaging personnel in
multicentre clinical trials will improve compliance with the IG
and ultimately deliver better cost-effective surrogate end-
points of clinical studies. Government efforts towards laws
and rules mandating the use of accredited QIB facilities in
multicentre studies could facilitate the desired change in the
quality of the results.
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